Frictionless Business and the Future of Life Insurance
The age of traditional business partnerships is long past. Today, strategic partnerships offer life insurers the ability to expand their businesses into new ecosystems. Whether investing in insurtechs or collaborating with partners in complementary industries, life insurers can build partnerships based not only on strategy, product and services but also on the merging of technology and the sharing of platforms.
How Liquid Biopsies Could Transform Insurance Medicine
Cancerous tumors shed whole cells or tiny bits of DNA and other genetic material into the bloodstream and other bodily fluids. This allows clinicians to potentially analyze blood samples to detect a tumor's unique mutations and offer a personalized treatment regimen, all without an invasive tissue biopsy.
Why Data Veracity Will Reshape Life Insurance
From its earliest days, life insurance has been fueled by data. Today, the industry is more data-driven than ever. Life insurers rely on data to make better operational, risk and pricing decisions. They use data to develop new products and business models. Increasingly, they leverage data to incentivize customers to reduce their exposure to risks and help them avoid incurring losses.
Wearable Technology in Life Insurance: Knowledge Is Power
Wearable technology has the potential to transform the life insurance industry by empowering insurers and insureds alike with valuable health knowledge.
Housecalls Underwriting Case Studies: July 2018
The July 2018 issue includes:
- FDA Bans Trans Fats
- ECG Puzzler
Life Conference Report: The Changing Industry (LOMA Resource)
At the 2018 Life Insurance Conference, industry leaders discussed important issues and strategies that will shape the future of the industry.
Impaired Risk Review: Idiopathic Pulmonary Fibrosis
A difficult and often fatal disease in older adults, idiopathic pulmonary fibrosis (IPF) is one of a spectrum of diseases called interstitial lung disease. The title accurately describes the process: Idiopathic (cause is unknown), pulmonary (affecting the lungs) and fibrosis (the normally expansive tissue in the lungs becomes hardened and fibrous). The disease can be localized or generalized, with generalized findings having a particularly poor prognosis. Usually not found until its later stages, CT scanning (particularly for lung cancer screening) has shown IPF to be more prevalent than previously thought.
Milliman IntelliScript Underwriting with Rx Based Models (Slides)
Slides from this presentation, given at the 2018 ACSW Spring Meeting, have been posted at the Actuaries’ Club of the Southwest website.